Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:NITE

Nightstar Therapeutics (NITE) Stock Price, News & Analysis

Nightstar Therapeutics logo

About Nightstar Therapeutics Stock (NASDAQ:NITE)

Advanced Chart

Key Stats

Today's Range
$31.67
$31.74
50-Day Range
$25.41
$25.41
52-Week Range
$9.59
$29.55
Volume
332 shs
Average Volume
185,808 shs
Market Capitalization
$1.06 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive NITE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nightstar Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

NITE Stock News Headlines

Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.
Knight Therapeutics price target lowered to C$6.25 from C$6.75 at Stifel
NITE The Nightview ETF
Thank you for supporting The Big Night In
See More Headlines

NITE Stock Analysis - Frequently Asked Questions

Nightstar Therapeutics PLC (NASDAQ:NITE) issued its earnings results on Tuesday, November, 13th. The company reported ($0.27) EPS for the quarter, beating analysts' consensus estimates of ($0.40) by $0.13.

Nightstar Therapeutics (NITE) raised $76 million in an initial public offering on Thursday, September 28th 2017. The company issued 5,400,000 shares at $13.00-$15.00 per share. Jefferies, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO and Wedbush PacGrow and Chardan were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Nightstar Therapeutics investors own include Canopy Growth (CGC), Cronos Group (CRON), OncoMed Pharmaceuticals (OMED), Portola Pharmaceuticals (PTLA), Ligand Pharmaceuticals (LGND), Neurocrine Biosciences (NBIX) and Sangamo Therapeutics (SGMO).

Company Calendar

Last Earnings
11/13/2018
Today
7/16/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological Products, Except Diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:NITE
CIK
1711675
Fax
N/A
Employees
47
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($1.26)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$36.86 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-30.89%
Return on Assets
-27.65%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
8.54
Quick Ratio
8.54

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$5.89 per share
Price / Book
5.39

Miscellaneous

Outstanding Shares
33,540,000
Free Float
N/A
Market Cap
$1.07 billion
Optionable
Not Optionable
Beta
2.84
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

This page (NASDAQ:NITE) was last updated on 7/17/2025 by MarketBeat.com Staff
From Our Partners